Mass fragmentometric determination of homovanillic acid in lumbar cerebrospinal fluid of schizophrenic patients during treatment with antipsychotic drugs.
D000328:Adult; D000367:Age Factors; D001714:Bipolar Disorder / Q000134:cerebrospinal fluid; D001921:Brain / Q000378:metabolism; D002746:Chlorpromazine / Q000627:therapeutic use; D002849:Chromatography, Gas; D003903:Deuterium; D004298:Dopamine / Q000378:metabolism; D005260:Female; D006220:Haloperidol / Q000627:therapeutic use; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid*; D006801:Humans; D008297:Male; D013058:Mass Spectrometry; D008875:Middle Aged; D010648:Phenylacetates / Q000134:cerebrospinal fluid*; D012559:Schizophrenia / Q000134:cerebrospinal fluid* / Q000188:drug therapy / Q000378:metabolism; D012737:Sex Factors; D013881:Thioridazine / Q000627:therapeutic use; D014149:Tranquilizing Agents / Q000627:therapeutic use*
D010648:Phenylacetates; D014149:Tranquilizing Agents; D003903:Deuterium; D006220:Haloperidol; D013881:Thioridazine; D002746:Chlorpromazine; D004298:Dopamine; D006719:Homovanillic Acid